Want to see IBIO full AI Analyst Report?

Ibio (IBIO) Price & Analysis

2,312 Followers

IBIO Stock Chart & Stats

$2.06

-$0.02(-0.74%)

At close: Jan 08 4:00 PM EST

$2.06

-$0.02(-0.74%)

Day’s Range― - ―

52-Week Range$0.56 - $3.82

Previous CloseN/A

Volume55.53K

Average Volume (3M)991.75K

Market Cap

$67.07M

Enterprise Value$154.77

Total Cash (Recent Filing)$74.80M

Total Debt (Recent Filing)$2.33M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Sep 29, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding49,678,562

10 Day Avg. Volume841,418

30 Day Avg. Volume991,754

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.54

Price to Sales (P/S)20.03

P/FCF Ratio-0.52

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$5.67

Price Target Upside175.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.31

Revenue Forecast (FY)$100.00K

Bulls Say, Bears Say

Bulls Say

Clinical-stage Transition (IBIO-600)Regulatory clearance to start a first‑in‑human Phase 1 for IBIO‑600 moves iBio into clinical development, creating durable value inflection opportunities (data readouts, partnerships, milestones). Clinical stage status strengthens ability to attract collaborators and non-dilutive deals.

Promising Preclinical Obesity Data (IBIO-610)Robust non-human primate biomarker and efficacy signals for IBIO‑610 — large Activin E reductions, fat‑selective weight loss, and improved combo outcomes with semaglutide — support a differentiated, long‑acting obesity candidate. This underpins durable commercial and partnership potential in a growing obesity therapeutics market.

Strengthened Board With Biotech VeteranAdding an experienced biotech and clinical development executive to the board improves governance and execution capability through clinical development and partnering inflection points. Long‑term, this raises the company’s ability to design trials, source collaborators, and navigate regulatory and financing milestones.

Bears Say

Sustained Negative Cash FlowPersistent operating and free cash flow burn of roughly $20–22M TTM indicates the business cannot self‑fund operations. Over months, this structural cash deficit necessitates external financing or partner deals, pressuring strategic flexibility and exposing the company to dilution risk when capital markets tighten.

Minimal Recurring Revenue And Large LossesVery low revenue and sizable operating/net losses show the company lacks commercialized products and scale. This structural lack of operating profitability means long lead times before internal revenue can underwrite development, increasing execution and funding risk over the medium term.

Funding Reliance Despite Low LeverageLow financial leverage reduces bankruptcy risk, but dependence on external capital and a fluctuating equity base signal repeated financings are likely. Structural reliance on equity/partnering creates dilution and timing risk that can delay programs or weaken negotiating leverage with partners.

Ibio News

iBio announces new preclinical data from IBIO-610 study

iBio (IBIO) announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a...

18d ago

IBIO

iBio Updates Governance Deadlines for 2026 Annual Meeting

Ibio ( ($IBIO) ) has shared an update. iBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders...

1d ago

IBIO

Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained

Analyst Patrick Dolezal of LifeSci Capital maintained a Buy rating on Ibio, retaining the price target of $5.00....

18d ago

IBIO

iBio Highlights Promising New Preclinical Obesity Antibody Data

The latest update is out from Ibio ( ($IBIO) ). On July 1, 2026, iBio reported new preclinical...

18d ago

IBIO

iBio initiated with an Outperform at Raymond James

Raymond James initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target iBio’s first antibody,...

1M ago

IBIO

iBio doses first participant in IBIO-600 trial

iBio (IBIO) announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the...

2M ago

IBIO

IBIO-600 First-in-Human Obesity Trial Puts iBio on Investors’ Radar

Ibio Inc ($IBIO) announced an update on their ongoing clinical study. The Phase 1 IBIO-600-CT001 study aims to...

2M ago

IBIO

iBio reports Q3 EPS (7c), consensus (6c)

“This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance...

2M ago

IBIO

iBio Strengthens Board with Appointment of Dr. Stoner

The latest announcement is out from Ibio ( ($IBIO) ). On May 7, 2026, iBio’s board appointed veteran...

2M ago

IBIO

Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Ibio today and set a price target of...

3M ago

IBIO

iBio Advances to Clinical Stage With IBIO-600 Trial

Ibio ( ($IBIO) ) has shared an announcement. On April 8, 2026, iBio announced it had received Clinical...

3M ago

IBIO

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

iBio (IBIO) announced IBIO-600 has received clinical trial notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval...

3M ago

IBIO

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

ACOG

IBIO

Insiders Rock Asana, Ibio, Redwire, AFLAC, Sibanye Stillwater

Insiders have been trading these 5 stocks: (($ASAN)), (($IBIO)), (($RDW)), (($AFL)) and (($SBSW)). Here is a breakdown of...

4M ago

AFL

RDW

IBIO FAQ

What was Ibio Inc’s price range in the past 12 months?

Ibio Inc lowest stock price was $0.56 and its highest was $3.82 in the past 12 months.

What is Ibio Inc’s market cap?

Ibio Inc’s market cap is $67.07M.

When is Ibio Inc’s upcoming earnings report date?

Ibio Inc’s upcoming earnings report date is Sep 29, 2026 which is in 72 days.

How were Ibio Inc’s earnings last quarter?

Ibio Inc released its earnings results on May 12, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.063 by -$0.007.

Is Ibio Inc overvalued?

According to Wall Street analysts Ibio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ibio Inc pay dividends?

Ibio Inc does not currently pay dividends.

What is Ibio Inc’s EPS estimate?

Ibio Inc’s EPS estimate is -0.06.

How many shares outstanding does Ibio Inc have?

Ibio Inc has 49,678,562 shares outstanding.

What happened to Ibio Inc’s price movement after its last earnings report?

Ibio Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.063. Following the earnings report the stock price went down -3.727%.

Which hedge fund is a major shareholder of Ibio Inc?

Currently, no hedge funds are holding shares in IBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ibio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.86%

Trailing 12-Months

Asset Growth

349.32%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ibio Inc

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

Ibio (IBIO) Earnings & Revenues

Historic Earnings Reports

IBIO Stock 12 Month Forecast

Average Price Target

$5.67

▲(175.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.666666666666667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2.1538461538461537,2.5576923076923075,2.9615384615384617,3.3653846153846154,3.769230769230769,4.173076923076923,4.576923076923077,4.980769230769231,5.384615384615385,5.788461538461538,6.1923076923076925,6.596153846153847,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2.051282051282051,2.3525641025641026,2.653846153846154,2.9551282051282053,3.2564102564102564,3.557692307692308,3.8589743589743595,4.160256410256411,4.461538461538462,4.762820512820513,5.064102564102565,5.365384615384616,{"y":5.666666666666667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2,2.25,2.5,2.75,3,3.25,3.5,3.75,4,4.25,4.5,4.75,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.749,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.659,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.811,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.823,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >